7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
de Moraes M et al. | Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts. | 2011 | Arch. Oral Biol. | pmid:21683340 |
Park H and Yim M | Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability. | 2007 | Arch. Pharm. Res. | pmid:17489366 |
Kim YH et al. | Dexamethasone inhibits the formation of multinucleated osteoclasts via down-regulation of beta3 integrin expression. | 2006 | Arch. Pharm. Res. | pmid:16964765 |
Bandeira F et al. | Bone markers and osteoporosis therapy. | 2014 | Arq Bras Endocrinol Metabol | pmid:25166041 |
Bennett BJ et al. | Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:16840715 |
Koole D et al. | Osteoprotegerin is associated with aneurysm diameter and proteolysis in abdominal aortic aneurysm disease. | 2012 | Arterioscler. Thromb. Vasc. Biol. | pmid:22516062 |
Moran CS et al. | Modulation of Kinin B2 Receptor Signaling Controls Aortic Dilatation and Rupture in the Angiotensin II-Infused Apolipoprotein E-Deficient Mouse. | 2016 | Arterioscler. Thromb. Vasc. Biol. | pmid:26966276 |
Sandberg WJ et al. | Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:16424351 |
Schoppet M et al. | RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. | 2002 | Arterioscler. Thromb. Vasc. Biol. | pmid:11950689 |
Clancy P et al. | Assessment of a serum assay for quantification of abdominal aortic calcification. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:17053174 |
Preusch MR et al. | Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis. | 2008 | Arterioscler. Thromb. Vasc. Biol. | pmid:18787189 |
Caidahl K et al. | Osteoprotegerin: a biomarker with many faces. | 2010 | Arterioscler. Thromb. Vasc. Biol. | pmid:20720194 |
Semb AG et al. | Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. | 2009 | Arterioscler. Thromb. Vasc. Biol. | pmid:19325145 |
Callegari A et al. | Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. | 2013 | Arterioscler. Thromb. Vasc. Biol. | pmid:23990207 |
Lieb W et al. | Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. | 2010 | Arterioscler. Thromb. Vasc. Biol. | pmid:20448212 |
Price PA et al. | Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11597934 |
Moran CS et al. | Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse. | 2014 | Arterioscler. Thromb. Vasc. Biol. | pmid:25301844 |
Abedin M et al. | Vascular calcification: mechanisms and clinical ramifications. | 2004 | Arterioscler. Thromb. Vasc. Biol. | pmid:15155384 |
Ovchinnikova O et al. | Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice--brief report. | 2009 | Arterioscler. Thromb. Vasc. Biol. | pmid:19592469 |
Hagedorn C et al. | Identification and functional analyses of molecular haplotypes of the human osteoprotegerin gene promoter. | 2009 | Arterioscler. Thromb. Vasc. Biol. | pmid:19661483 |
Dhore CR et al. | Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11742876 |
Orita Y et al. | Role of osteoprotegerin in arterial calcification: development of new animal model. | 2007 | Arterioscler. Thromb. Vasc. Biol. | pmid:17615383 |
Jansson AM et al. | Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes. | 2012 | Arterioscler. Thromb. Vasc. Biol. | pmid:23023373 |
Gravallese EM et al. | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. | 2001 | Arthritis Res. | pmid:11178122 |
Schett G et al. | The role of osteoprotegerin in arthritis. | 2003 | Arthritis Res. Ther. | pmid:12932284 |
Tat SK et al. | Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. | 2007 | Arthritis Res. Ther. | pmid:17996099 |
MartÃnez-Calatrava MJ et al. | RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. | 2012 | Arthritis Res. Ther. | pmid:22709525 |
Dalbeth N et al. | Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. | 2010 | Arthritis Res. Ther. | pmid:20796300 |
Findlay D et al. | Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. | 2008 | Arthritis Res. Ther. | pmid:18182105 |
Kato G et al. | The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. | 2015 | Arthritis Res. Ther. | pmid:26373710 |
Stolina M et al. | RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. | 2009 | Arthritis Res. Ther. | pmid:20003323 |
Audo R et al. | Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. | 2015 | Arthritis Res. Ther. | pmid:26220665 |
Nich C et al. | Oestrogen deficiency modulates particle-induced osteolysis. | 2011 | Arthritis Res. Ther. | pmid:21696618 |
Kubota T et al. | NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. | 2007 | Arthritis Res. Ther. | pmid:17892600 |
Carmona-Fernandes D et al. | Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. | 2011 | Arthritis Res. Ther. | pmid:22027240 |
Poubelle PE et al. | Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. | 2007 | Arthritis Res. Ther. | pmid:17341304 |
D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
Brabnikova-Maresova K et al. | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. | 2014 | Arthritis Res. Ther. | pmid:25280749 |
Knevel R et al. | A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. | 2014 | Arthritis Res. Ther. | pmid:24886600 |
Granet C et al. | Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. | 2004 | Arthritis Res. Ther. | pmid:15142264 |
Juarranz Y et al. | Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. | 2005 | Arthritis Res. Ther. | pmid:16207319 |
Görtz B et al. | Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. | 2005 | Arthritis Res. Ther. | pmid:16207331 |
Revu S et al. | Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate. | 2013 | Arthritis Res. Ther. | pmid:24295447 |
Boyce BF and Xing L | Biology of RANK, RANKL, and osteoprotegerin. | 2007 | Arthritis Res. Ther. | pmid:17634140 |
Crotti TN et al. | The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. | 2012 | Arthritis Res. Ther. | pmid:23146195 |
Marotte H et al. | Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. | 2005 | Arthritis Res. Ther. | pmid:15642135 |
Hofbauer LC and Heufelder AE | The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. | 2001 | Arthritis Rheum. | pmid:11229454 |
Cohen S | Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. | 2006 | Arthritis Rheum. | pmid:16463406 |
Haynes D et al. | Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. | 2008 | Arthritis Rheum. | pmid:18576301 |
Ziolkowska M et al. | High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. | 2002 | Arthritis Rheum. | pmid:12124857 |
Campagnuolo G et al. | Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. | 2002 | Arthritis Rheum. | pmid:12124878 |
Schett G et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | 2003 | Arthritis Rheum. | pmid:12847699 |
Marzaioli V et al. | Histamine contributes to increased RANKL to osteoprotegerin ratio through altered nuclear receptor 4A activity in human chondrocytes. | 2012 | Arthritis Rheum. | pmid:22674155 |
Catrina AI et al. | Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. | 2006 | Arthritis Rheum. | pmid:16385498 |
Hase H et al. | Coculture of osteoclast precursors with rheumatoid synovial fibroblasts induces osteoclastogenesis via transforming growth factor beta-mediated down-regulation of osteoprotegerin. | 2008 | Arthritis Rheum. | pmid:18975335 |
Catrina AI and Klareskog L | Effects of disease-modifying antirheumatic drug treatment on the expression of RANKL and osteoprotegerin in synovial tissue: comment on the article by Haynes et al. | 2008 | Arthritis Rheum. | pmid:18975354 |
Koufany M et al. | The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway. | 2013 | Arthritis Rheum. | pmid:23982996 |
Tunyogi-Csapo M et al. | Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. | 2008 | Arthritis Rheum. | pmid:18668542 |
Kadri A et al. | Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. | 2008 | Arthritis Rheum. | pmid:18668550 |
Takayanagi H et al. | Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. | 2000 | Arthritis Rheum. | pmid:10693864 |
Rifas L and Weitzmann MN | A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. | 2009 | Arthritis Rheum. | pmid:19877052 |
van Lent PL et al. | Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation. | 2006 | Arthritis Rheum. | pmid:17133594 |
Dalle Carbonare L et al. | Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. | 2009 | Arthritis Rheum. | pmid:19877060 |
Schett G et al. | Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. | 2009 | Arthritis Rheum. | pmid:19714640 |
Yang SY et al. | Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. | 2002 | Arthritis Rheum. | pmid:12355500 |
Shimizu S et al. | Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. | 2007 | Arthritis Rheum. | pmid:17907189 |
Lubberts E et al. | Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. | 2002 | Arthritis Rheum. | pmid:12428250 |
Vandooren B et al. | The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. | 2008 | Arthritis Rheum. | pmid:18311801 |
Loddenkemper K and Burmester GR | What is the rank of RANKL in spondylarthritis? | 2008 | Arthritis Rheum. | pmid:18311809 |
Cho TJ et al. | Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. | 2003 | Arthritis Rheum. | pmid:14558090 |
Sanchez C et al. | Regulation of subchondral bone osteoblast metabolism by cyclic compression. | 2012 | Arthritis Rheum. | pmid:22034083 |
Alvarez L et al. | Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. | 2003 | Arthritis Rheum. | pmid:12632438 |
Kim JY et al. | Osteoprotegerin causes apoptosis of endothelial progenitor cells by induction of oxidative stress. | 2013 | Arthritis Rheum. | pmid:23666878 |
Kim YG et al. | Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. | 2010 | Arthritis Rheum. | pmid:20112365 |
Moreno-Rubio J et al. | Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. | 2010 | Arthritis Rheum. | pmid:20112374 |
Mosheimer BA et al. | Expression and function of RANK in human monocyte chemotaxis. | 2004 | Arthritis Rheum. | pmid:15248232 |
Hughes C et al. | Human single-chain variable fragment that specifically targets arthritic cartilage. | 2010 | Arthritis Rheum. | pmid:20131274 |
Schett G et al. | Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. | 2005 | Arthritis Rheum. | pmid:15880601 |
Geusens PP et al. | The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. | 2006 | Arthritis Rheum. | pmid:16736519 |
Geboes L et al. | Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-gamma receptor by triggering tumor necrosis factor alpha-driven osteoclastogenesis. | 2007 | Arthritis Rheum. | pmid:17665444 |
Lee CK et al. | Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. | 2004 | Arthritis Rheum. | pmid:15593184 |
Neumann E et al. | The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. | 2005 | Arthritis Rheum. | pmid:16200575 |
Redlich K et al. | Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. | 2002 | Arthritis Rheum. | pmid:11920416 |
Makrygiannakis D et al. | Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. | 2006 | Arthritis Rheum. | pmid:16646024 |
Balani D et al. | Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro. | 2013 | Arthritis Rheum. | pmid:23124514 |
Komuro H et al. | The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. | 2001 | Arthritis Rheum. | pmid:11762937 |
Mahoney DJ et al. | TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. | 2011 | Arthritis Rheum. | pmid:21162099 |
Audo R et al. | Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. | 2011 | Arthritis Rheum. | pmid:21305500 |
Bolon B et al. | Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. | 2002 | Arthritis Rheum. | pmid:12483715 |
Golmia RP et al. | Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacós et al. | 2002 | Arthritis Rheum. | pmid:12483748 |
Polzer K et al. | Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. | 2011 | Arthritis Rheum. | pmid:21360496 |
Oshita K et al. | Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. | 2011 | Arthritis Rheum. | pmid:21360521 |
Zwerina J et al. | Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. | 2004 | Arthritis Rheum. | pmid:14730626 |
Koreny T et al. | The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. | 2006 | Arthritis Rheum. | pmid:17009257 |
Brechter AB and Lerner UH | Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression. | 2007 | Arthritis Rheum. | pmid:17328065 |
Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |
Rouster-Stevens KA et al. | RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. | 2007 | Arthritis Rheum. | pmid:17328075 |
Jiang J et al. | LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. | 2005 | Artif Cells Blood Substit Immobil Biotechnol | pmid:16317958 |
Bilgin E et al. | Markers of bone metastases in breast and lung cancers. | 2012 | Asian Pac. J. Cancer Prev. | pmid:23167338 |
Chen T et al. | High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor. | 2006 | Assay Drug Dev Technol | pmid:16945012 |